Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
The findings, based on an analysis of records from 2.5 million VA patients, support much of what scientists already suspected ...
As GLP-1 medications like Ozempic, Wegovy, Zepbound, and Mounjaro gain popularity, doctors are observing a surge in patients ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Novo Nordisk on Friday announced early-stage trial results for its amycretin obesity drug for subcutaneous injection, saying ...
Over 2 million people were included in new research to test these drugs against 175 different health outcomes.
Novo Nordisk (NVO) stock gains on promising Phase 1/2 data for the drugmaker's new weight loss drug amycretin. Read more here ...
The diabetes startup is prescribing GLP-1 drugs for weight loss to help employers manage costs. Its CEO says it's nearing ...